Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HOLX vs PHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HOLX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

HOLX Overall Winner 6-Pillar Tally: HOLX 3 – 2 PHG (1 Tie) Matrix Metrics: HOLX 7 – 3 PHG

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HOLX vs PHG
HOLX NASDAQ Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
PHG NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$28.61
-2.19% 1D
Market Cap $28.6B
TTM Revenue $17.8B
Forward P/E 14.0x
Beta / 30D Vol 0.71β · 38% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 15.0 Fund 39.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.0% over 20 days), RSI 51
RSI-14: 51.0 · SMA20: $29.08 · SMA50: $26.59

6-Pillar Scorecard Institutional Category Breakdown (HOLX 3 – 2 PHG)

Columns: Metric · HOLX · PHG
1. Valuation Multiples PHG
Forward P/E 20.1x 14.0x
Trailing P/E 31.4x 25.4x
PEG Ratio 1.66x 0.90x
EV / Revenue 4.1x 1.9x
2. Growth & Scale HOLX
Revenue Growth (YoY) +2.5% +2.1%
Earnings Growth (YoY) -9.2% -85.4%
TTM Revenue (USD) $4.13B $17.8B
Market Cap $16.9B $28.6B
3. Profitability & Quality HOLX
Gross Margin 60.4% 46.4%
Operating Margin 23.0% 8.8%
Net Profit Margin 13.2% 5.4%
Return on Equity (ROE) 10.9% 8.6%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $1.35B EBITDA $1.82B
Cash Flow Margin 32.7% EBITDA Mgn 10.3%
Net Cash / Leverage $23.51 Book/Sh · 10.9% ROE $5.39B Net Debt (0.70x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PHG
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 6.3% (3rd %ile) 111.5% (51st %ile)
Put/Call OI Skew 6.20x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 37.4% of Rev ($1.54B) 37.6% of Rev ($6.68B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HOLX (7) vs PHG (3)
Institutional Metric HOLX PHG Criterion Row Edge
Market Capitalization
Scale
$16.9B $28.6B Larger Scale PHG
Trailing P/E Ratio
Valuation
31.4x 25.4x Lower Multiple PHG
Forward P/E Ratio
Valuation
20.1x 14.0x Lower Multiple PHG
Revenue Growth (YoY)
Growth
+2.5% +2.1% Higher Growth HOLX
Operating Margin (TTM)
Profitability
23.0% 8.8% Higher Margin HOLX
Net Profit Margin
Profitability
13.2% 5.4% Higher Margin HOLX
Return on Equity (ROE)
Capital Efficiency
10.9% 8.6% Higher ROE HOLX
52-Week Range Position
Momentum
100% ($52–$76) 51% ($24–$33) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol 0.71β · 38% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY) 40.3 / 100 (SELL) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B $17.8B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4% 46.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev 0.90x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) $1.82B ($5.39B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HOLX +8.63 pp
HOLX: +0.34% · PHG: -8.29%
3M Horizon HOLX +1.46 pp
HOLX: +1.94% · PHG: +0.48%
6M Horizon HOLX +1.96 pp
HOLX: +2.48% · PHG: +0.52%
1Y Horizon HOLX +1.96 pp
HOLX: +2.48% · PHG: +0.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs PHG. Trailing 12-month operating profitability (HOLX 23.0% vs PHG 8.8%) and valuation multiples (HOLX 20.1x vs PHG 14.0x Forward P/E) are benchmarked directly in Pillar 4 below.

HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x
PHG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$17.8B
Gross Margin46.4%
Op. Margin8.8%
ROE / Fwd P/E8.6% · 14.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHG SURGE
12d in phase · OBV DISTRIBUTION
Current IV 111.5%
IV Percentile 51st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published
PHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $28.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($6.68B)
90D Engineering Disclosures 0 Published

Investor FAQ HOLX vs PHG Key Questions & Quantitative Answers

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin). Technically, HOLX sits in a Neutral phase (RSI 69.0, UNCLASSIFIED options structure) and PHG sits in a Markup phase (RSI 51.0, SURGE options structure).

HOLX leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $17.8B TTM revenue (46.4% gross margin, 8.8% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $17.8B for PHG. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($6.68B) (0 disclosures) for PHG.

PHG screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas PHG trades at 14.0x Forward P/E, 25.4x Trailing P/E, 0.90x PEG, and 1.9x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus PHG (8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, PHG carries 111.5% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.71β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.